Cabio Biotech (Wuhan) Co., Ltd. (SHA:688089)

Market Cap	3.23B +4.6%
Revenue (ttm)	596.47M +17.9%
Net Income	169.67M +47.7%
EPS	1.01 +48.8%
Shares Out	166.80M
PE Ratio	19.18
Forward PE	18.02
Dividend	0.20 (1.04%)
Ex-Dividend Date	Jul 10, 2025

Volume	1,778,468
Average Volume	3,071,498
Open	19.46
Previous Close	19.45
Day's Range	19.37 - 19.64
52-Week Range	18.70 - 31.13
Beta	0.49
RSI	38.59
Earnings Date	Apr 23, 2026

About Cabio Biotech (Wuhan)

Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. It offers human and animal nutrition, personal care, and synthetic biology products. The company was founded in 1999 and is based in Wuhan, the People’s Republic of China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 574
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688089

Financial Performance

In 2024, Cabio Biotech (Wuhan)'s revenue was 555.59 million, an increase of 25.19% compared to the previous year's 443.80 million. Earnings were 124.21 million, an increase of 35.94%.